WASHINGTON—The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc.'s challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal ...